Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KL-A167 + cisplatin + gemcitabine
- Development stage
- Unknown
- Lead developer
- Kelun-Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
KL-A167 + cisplatin + gemcitabine is a combination regimen consisting of KL-A167 (tagitanlimab), cisplatin, and gemcitabine, primarily indicated for the treatment of recurrent or metastatic nasopharyngeal carcinoma. KL-A167 is a fully humanized monoclonal antibody targeting programmed cell death-ligand 1 (PD-L1), designed to inhibit the PD-1/PD-L1 immune checkpoint pathway and restore anti-tumor immunity. When used in combination with cytotoxic chemotherapeutic agents cisplatin (a platinum-based DNA crosslinking agent) and gemcitabine (a nucleoside analog antimetabolite), the regimen provides immunotherapeutic and cytotoxic mechanisms to treat cancer. Clinical trial and regulatory data show this specific combination is approved by Chinese regulatory authorities for recurrent/metastatic nasopharyngeal cancer[5].
- Brand names
- Cotelet
- Other names
- KL-A167 + cisplatin + gemcitabinetagitanlimab + cisplatin + gemcitabine
02
Targets
DNA polymerase familyCD274 (Programmed cell death protein 1 ligand 1)DNARNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on KL-A167 + cisplatin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KL-A167 + cisplatin + gemcitabine.